我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

In the Early Stages of the COVID-19 Epidemic, Weighing Evidence and First-Hand Experience

Levra S

Background: Severe acute respiratory pattern coronavirus 2(SARS- CoV- 2) is the causative agent of coronavirus complaint 2019(COVID- 19), which has fleetly come epidemic in Italy and other European countries. The complaint diapason ranges from asymptomatic/ mildly characteristic donations to acute respiratory failure. At the present time the absolute number of severe cases taking ventilator support is reaching or indeed surpassing the ferocious care unit bed capacity in the most affected regions and countries.

Objects: To narratively epitomize the available literature on the operation of COVID- 19 in order to combine current substantiation and frontline opinions and to give balanced answers to pressing clinical questions.

Sources: Inductive PubMed hunt for publications applicable to the content.

Content: The available literature and the authors' frontline- grounded opinion are epitomized in brief narrative answers to named clinical questions, with a conclusive statement handed for each answer.

Counteraccusations: Numerous off- marker antiviral andanti-inflammatory medicines are presently being administered to cases with COVID- 19. Physicians must be apprehensive that, as they aren't supported by highposition substantiation, these treatments may frequently be immorally maintainable only in those worsening cases doubtful to ameliorate only with probative care, and who cannot be enrolled onto randomized clinical trials. Access to well- designed randomized controlled trials should be expanded as much as possible because it's the most secure way to change for the better our approach to COVID- 19 cases.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。